Navigation Links
BioCryst Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009
Date:7/28/2009

BIRMINGHAM, Ala., July 28 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals (Nasdaq: BCRX) today announced that its second quarter 2009 financial results will be released on Thursday, July 30, 2009. BioCryst will host a conference call and Web cast at 11:00 a.m. Eastern Time to discuss the financial results and provide an update on the Company's programs. The call will be led by Jon P. Stonehouse, President and Chief Executive Officer, Stuart Grant, Chief Financial Officer and Dr. William P. Sheridan, Chief Medical Officer.

The Web cast can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed. To participate in the conference call, please dial 1-877-627-6566 (United States) or 1-719-325-4922 (International). No passcode is needed for the call. The audio portion of the Web cast will be archived and available for replay for at least 14 days.

About BioCryst

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule pharmaceuticals that block key enzymes involved in oncology, infectious and autoimmune diseases. BioCryst has two product candidates in pivotal clinical trials; peramivir, an anti-viral for influenza, and forodesine, a purine nucleoside phosphorylase (PNP) inhibitor for cutaneous T-cell lymphoma (CTCL). Utilizing crystallography and structure-based drug design, BioCryst continues to expand its portfolio of next-generation therapeutic candidates with the potential to address the unmet medical needs of patients and physicians. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings, Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at www.biocryst.com.

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at www.shareholder.com/biocryst/edgar.cfm.

BCRXW


'/>"/>
SOURCE BioCryst Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioCryst Reports Fourth Quarter and Year End 2008 Financial Results and Provides Corporate Update
2. BioCryst to Present at the J.P. Morgan 27th Annual Healthcare Conference
3. BioCryst to Present Three Posters During the 50th American Society of Hematology Annual Meeting and Exposition
4. BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
5. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
6. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
7. BioCryst to Present at the JMP Healthcare Focus Conference
8. BioCryst to Present at UBS 2008 Global Life Sciences Conference
9. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
10. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
11. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the ... today the Clinical Reach Virtual Patient Encounter CONSULT module which enables both ... physician and clinical trial team. , Using the CONSULT module, patients and physicians can ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in ... Trials Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio ... practical tips, tools, and strategies for clinical researchers. , “The landscape of how ...
Breaking Biology Technology:
(Date:6/2/2016)... 2, 2016 The Department of Transport ... the 44 million US Dollar project, for the , ... including Personalization, Enrolment, and IT Infrastructure , to ... production and implementation of Identity Management Solutions. Numerous renowned international ... Decatur was selected for the most compliant ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):